← All trials
NCT05176626
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Sep 30, 2025
- Completion date
- Sep 30, 2025
- First posted
- Jan 4, 2022
- Last posted
- Dec 20, 2022
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Wake Forest UniversityLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- HealthPartners InstituteCollaborator
- Johns Hopkins UniversityCollaborator
- Kaiser PermanenteCollaborator
- Wake Forest UniversityOverall official - principal investigator
- Biomedical Research Institute of New MexicoCollaborator
- University of Texas at HoustonCollaborator
- Kvk Tech IncCollaborator
- Weight Watchers InternationalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.